84 related articles for article (PubMed ID: 11907082)
1. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity.
Tiroch K; Stockmeyer B; Frank C; Valerius T
J Immunol; 2002 Apr; 168(7):3275-82. PubMed ID: 11907082
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
3. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells.
Stockmeyer B; Beyer T; Neuhuber W; Repp R; Kalden JR; Valerius T; Herrmann M
J Immunol; 2003 Nov; 171(10):5124-9. PubMed ID: 14607911
[TBL] [Abstract][Full Text] [Related]
4. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.
Ma Y; Xiang D; Sun J; Ding C; Liu M; Hu X; Li G; Kloecker G; Zhang HG; Yan J
J Immunol; 2013 Jun; 190(11):5588-99. PubMed ID: 23630363
[TBL] [Abstract][Full Text] [Related]
5. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
6. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity.
Horner H; Frank C; Dechant C; Repp R; Glennie M; Herrmann M; Stockmeyer B
J Immunol; 2007 Jul; 179(1):337-45. PubMed ID: 17579054
[TBL] [Abstract][Full Text] [Related]
7. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
8. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
[TBL] [Abstract][Full Text] [Related]
9. Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro.
Brodowicz T; Wiltschke C; Budinsky AC; Krainer M; Steger GG; Zielinski CC
Int J Cancer; 1997 Dec; 73(6):875-9. PubMed ID: 9399669
[TBL] [Abstract][Full Text] [Related]
10. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity.
McCall AM; Shahied L; Amoroso AR; Horak EM; Simmons HH; Nielson U; Adams GP; Schier R; Marks JD; Weiner LM
J Immunol; 2001 May; 166(10):6112-7. PubMed ID: 11342630
[TBL] [Abstract][Full Text] [Related]
11. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
12. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
13. Influence of variable N-glycosylation on the cytolytic potential of chimeric CD19 antibodies.
Barbin K; Stieglmaier J; Saul D; Stieglmaier K; Stockmeyer B; Pfeiffer M; Lang P; Fey GH
J Immunother; 2006; 29(2):122-33. PubMed ID: 16531813
[TBL] [Abstract][Full Text] [Related]
14. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
[TBL] [Abstract][Full Text] [Related]
16. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
[TBL] [Abstract][Full Text] [Related]
18. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
[TBL] [Abstract][Full Text] [Related]
19. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells.
Gritzapis AD; Mamalaki A; Kretsovali A; Papamatheakis J; Belimezi M; Perez SA; Baxevanis CN; Papamichail M
Br J Cancer; 2003 Apr; 88(8):1292-300. PubMed ID: 12698199
[TBL] [Abstract][Full Text] [Related]
20. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
